Studies
Primary studies
26,293 studies included by 1,022 non-Cochrane dental reviews extracted from full text, one record per study, so a study included by several reviews is counted once. Most are randomized trials; etiology and diagnostic reviews also include observational and accuracy studies. Cochrane reviews and reviews with only their headline outcomes do not list their included studies here yet.
ReviewStudies included by Beyond [177Lu]Lu-PSMA: a meta-analysis of safety and efficacy of emerging PSMA radioligand therapy agents.. Show all studies
| Study | Year | Reviews | Review outcomes linked | Trial data |
|---|---|---|---|---|
| RECIP 1.0 + PSA for response assessment in mCRPC patients treated with 225Ac / 177Lu PSMA combination therapy. Sheikh 2025 · Sheikh Gabriel T, Delker Astrid, et al. · EJNMMI research PMID:40038098 | 2025 | 2 | 1 | not extracted yet |
| 225 Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177 Lu-PSMA-617 Radioligand Therapy : Pilot Experience From a Prospective Registry. Rosar 2024 · Rosar Florian, Burgard Caroline, et al. · Clinical nuclear medicine PMID:38769643 | 2024 | 2 | 1 | not extracted yet |
| Deescalated 225Ac-PSMA-617 Versus 177Lu/225Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients. Rathke 2024 · Rathke Hendrik, Winter Erik, et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine PMID:38844358 | 2024 | 2 | 1 | not extracted yet |
| Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients… Rosar 2021 (Theranostics) · Rosar Florian, Hau Fabian, et al. · Theranostics PMID:33754047 | 2021 | 2 | 1 | not extracted yet |
| Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis. Rosar 2021 (Pharmaceutics) · Rosar Florian, Krause Jonas, et al. · Pharmaceutics PMID:34069003 | 2021 | 2 | 1 | not extracted yet |
| 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Khreish 2020 · Khreish Fadi, Ebert Niklas, et al. · European journal of nuclear medicine and molecular imaging PMID:31758224 | 2020 | 2 | 1 | not extracted yet |
| Refining the clinical utility of [177Lu]Lu/[225Ac]Ac-PSMA tandem RLT in patients with metastatic castration resistant prostate cancer. Widjaja 2025 · Widjaja Liam, Hornfeck Johannes, et al. · European journal of nuclear medicine and molecular imaging PMID:41174098 | 2026 | 1 | none stated | not extracted yet |
| First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant… Buteau 2025 · Buteau James P, Kostos Louise, et al. · The Lancet Oncology DOI:10.1016/s1470-2045(25)00332-8 | 2025 | 1 | none stated | not extracted yet |
| Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand… Perrone 2025 · Perrone Elisabetta, Giordano Alessandro, et al. · Cancers PMID:39941774 | 2025 | 1 | none stated | not extracted yet |
| The efficacy and safety of 225Ac-PSMA-617 in metastatic castration-resistant prostate cancer. Ma 2025 · Ma Jiao, Zhang Yu, et al. · Frontiers in oncology PMID:40094004 | 2025 | 1 | none stated | not extracted yet |
| First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant… Buteau 2025 · Buteau James P, Kostos Louise, et al. · The Lancet. Oncology PMID:40617237 | 2025 | 1 | none stated | not extracted yet |
| Pilot experience of [161Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registry. Rosar 2025 · Rosar Florian, Burgard Caroline, et al. · Theranostics PMID:40963912 | 2025 | 1 | none stated | not extracted yet |
| Initial Multicenter Experience with [161Tb]Tb-PSMA in [177Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer: Preliminary Results. Kucuk 2025 · Kucuk Nuriye Ozlem, Coskun Nazim, et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine PMID:41043996 | 2025 | 1 | none stated | not extracted yet |
| Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. Sathekge 2024 · Sathekge Mike M, Lawal Ismaheel O, et al. · The Lancet. Oncology PMID:38218192 | 2024 | 1 | none stated | not extracted yet |
| [161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to… Schaefer-Schuler 2024 · Schaefer-Schuler Andrea, Burgard Caroline, et al. · Theranostics PMID:38505615 | 2024 | 1 | none stated | not extracted yet |
| A phase 2, single-arm trial evaluating 131 I-PSMA-1095 targeted radioligand therapy for metastatic castration-resistant prostate cancer. Liu 2024 · Liu Richard F, Ferrario Cristiano, et al. · Nuclear medicine communications PMID:38726601 | 2024 | 1 | none stated | not extracted yet |
| From Despair to Hope: First Arabic Experience of 177Lu-PSMA and 161Tb-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer. Al-Ibraheem 2024 · Al-Ibraheem Akram, Abdlkadir Ahmed Saad, et al. · Cancers PMID:38893095 | 2024 | 1 | none stated | not extracted yet |
| 225Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings. Sathekge 2023 · Sathekge Mike, Bruchertseifer Frank, et al. · European journal of nuclear medicine and molecular imaging PMID:36864360 | 2023 | 1 | none stated | not extracted yet |
| Long-term survival outcomes of salvage [225Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic… Ballal 2023 · Ballal Sanjana, Yadav Madhav P, et al. · European journal of nuclear medicine and molecular imaging PMID:37462775 | 2023 | 1 | none stated | not extracted yet |
| Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer. Alan-Selcuk 2023 · Alan-Selcuk Nalan, Beydagi Gamze, et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine PMID:37620050 | 2023 | 1 | none stated | not extracted yet |
| A Phase 1, Open-label, Dose-Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the… Laccetti 2023 · Laccetti Andrew L, Bodei Lisa, et al. · Clinical nuclear medicine PMID:37812518 | 2023 | 1 | none stated | not extracted yet |
| Comparative Analysis of Morphological and Functional Effects of 225Ac- and 177Lu-PSMA Radioligand Therapies (RLTs) on Salivary Glands. Feuerecker 2023 · Feuerecker Benedikt, Gafita Andrei, et al. · International journal of molecular sciences PMID:38069166 | 2023 | 1 | none stated | not extracted yet |
| mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis. Sathekge 2022 · Sathekge Mike, Bruchertseifer Frank, et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine PMID:35177427 | 2022 | 1 | none stated | not extracted yet |
| First Clinical Results for PSMA-Targeted α-Therapy Using 225Ac-PSMA-I&T in Advanced-mCRPC Patients. Zacherl 2021 · Zacherl Mathias Johannes, Gildehaus Franz Josef, et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine PMID:33008928 | 2021 | 1 | none stated | not extracted yet |
| Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted… Van der Doelen 2021 · van der Doelen Maarten J, Mehra Niven, et al. · Urologic oncology PMID:33353867 | 2021 | 1 | none stated | not extracted yet |
| Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer-a systematic review and meta-analysis. Satapathy 2020 · Satapathy Swayamjeet, Sood Ashwani, et al. · Prostate cancer and prostatic diseases PMID:33746213 | 2021 | 1 | none stated | not extracted yet |
| Therapeutic efficacy of 225Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based… Sen 2021 · Sen Ishita, Thakral Parul, et al. · Annals of nuclear medicine PMID:34059998 | 2021 | 1 | none stated | not extracted yet |
| 225Ac-Prostate-Specific Membrane Antigen Therapy for Castration-Resistant Prostate Cancer: A Single-Center Experience. Sanli 2021 · Sanli Yasemin, Kuyumcu Serkan, et al. · Clinical nuclear medicine PMID:34593693 | 2021 | 1 | none stated | not extracted yet |
| Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand… Sathekge 2020 · Sathekge Mike, Bruchertseifer Frank, et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine PMID:31101746 | 2020 | 1 | none stated | not extracted yet |
| Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients. Yadav 2020 · Yadav Madhav Prasad, Ballal Sanjana, et al. · Theranostics PMID:32802197 | 2020 | 1 | none stated | not extracted yet |
| 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Sathekge 2019 · Sathekge Mike, Bruchertseifer Frank, et al. · European journal of nuclear medicine and molecular imaging PMID:30232539 | 2019 | 1 | none stated | not extracted yet |
| Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding… Kratochwil 2018 · Kratochwil Clemens, Bruchertseifer Frank, et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine PMID:29326358 | 2018 | 1 | none stated | not extracted yet |
| Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095. Afshar-Oromieh 2017 · Afshar-Oromieh Ali, Haberkorn Uwe, et al. · European journal of nuclear medicine and molecular imaging PMID:28280855 | 2017 | 1 | none stated | not extracted yet |
| Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding. Kratochwil 2017 · Kratochwil Clemens, Bruchertseifer Frank, et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine PMID:28408529 | 2017 | 1 | none stated | not extracted yet |